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Abstract
Background: Observational studies suggest high prenatal vitamin D intake may be associated with reduced childhood
wheezing. We examined the effect of prenatal vitamin D on childhood wheezing in an interventional study.
Methods: We randomised 180 pregnant women at 27 weeks gestation to either no vitamin D, 800 IU ergocalciferol daily
until delivery or single oral bolus of 200,000 IU cholecalciferol, in an ethnically stratified, randomised controlled trial.
Supplementation improved but did not optimise vitamin D status. Researchers blind to allocation assessed offspring at 3
years. Primary outcome was any history of wheeze assessed by validated questionnaire. Secondary outcomes included
atopy, respiratory infection, impulse oscillometry and exhaled nitric oxide. Primary analyses used logistic and linear
regression.
Results: We evaluated 158 of 180 (88%) offspring at age 3 years for the primary outcome. Atopy was assessed by skin test
for 95 children (53%), serum IgE for 86 (48%), exhaled nitric oxide for 62 (34%) and impulse oscillometry of acceptable
quality for 51 (28%). We found no difference between supplemented and control groups in risk of wheeze [no vitamin D: 14/
50 (28%); any vitamin D: 26/108 (24%) (risk ratio 0.86; 95% confidence interval 0.49, 1.50; P = 0.69)]. There was no significant
difference in atopy, eczema risk, lung function or exhaled nitric oxide between supplemented groups and controls.
Conclusion: Prenatal vitamin D supplementation in late pregnancy that had a modest effect on cord blood vitamin D level,
was not associated with decreased wheezing in offspring at age three years.
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Introduction
Several observational studies have suggested a protective effect
of higher maternal vitamin D intake during pregnancy on risk of
wheezing [1–3], asthma and allergic rhinitis [4], and eczema [3] in
offspring. Dietary intake of vitamin D makes a relatively small
contribution to overall vitamin D status, and apparent effects of
vitamin D intake may be confounded by other correlated
nutrients. These studies did not report outcomes in relation to
maternal serum 25-hydroxyvitamin D (25(OH)D) concentration,
which takes account of skin synthesis, our primary source of
vitamin D, and is the gold standard measure of vitamin D status
[5,6]. Observational studies of maternal or cord 25(OH)D levels
and child health have yielded conflicting results, with higher
25(OH)D levels associated with increased risk of eczema and
asthma [7], reduced risk of respiratory infection and preschool
wheezing [8], and no association with asthma [8] or lung function
[9] all reported.
There are plausible biological mechanisms for an association
between prenatal 25(OH)D status and wheezing. Developmental
programming of lung function and immune responses occurs
during pregnancy [10,11]. The active metabolite of vitamin D,
1,25-dihydroxyvitamin D, has been shown in animal and in vitro
models to have potent immune effects [12] and a role in early
lung development [13]. Current recommendations in the United
Kingdom are for provision of 10 mg/day (400 IU/day) to all
pregnant women [14]. Vitamin D insufficiency is nevertheless
very common during pregnancy [15–17], and it has been
proposed that prenatal vitamin D supplementation may prevent
childhood wheezing and asthma [18]. We assessed children
whose mothers had taken part in a randomised controlled trial of
prenatal vitamin D supplementation, to determine whether
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supplementation prevented wheezing or allergic disease in the
first 3 years of life [19].
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Ethics Statement
St. Mary’s Hospital Research Ethics Committee approved the
follow up study (10/H0712/13) and women gave written informed
consent to participation for themselves and their child. Where
women only consented to interview over the telephone, verbal
consent was taken in place of written consent and this was
approved by the Ethics Committee. For each participant who gave
verbal consent, this was taken and documented by 2 separate
members of the research team.
Study Subjects
This was a prospective follow up study of the offspring of
women who took part in an ethnically stratified, parallel group,
randomised controlled trial of vitamin D supplementation in
pregnancy at St Mary’s Hospital London, a university-affiliated
hospital prenatal clinic, between April and November 2007. The
original trial was conducted to determine the effect of supplemen-
tation on 25(OH)D status of mothers in 4 specific ethnic groups,
and their babies, at delivery [19]. Eligible participants were
women presenting at 27 weeks gestation for routine glucose
challenge test from the following ethnic groups: Asian, Middle
Eastern, Black and White. Ethnic group was assigned based on
participant self-report. Exclusion criteria were known sarcoidosis,
osteomalacia, renal dysfunction or tuberculosis.
Study Design
Women were randomised at 27 weeks gestation to no treatment
(control), 800 IU ergocalciferol until delivery (daily), or a single
oral dose of 200,000 IU cholecalciferol (bolus). The randomisation
Figure 1. Recruitment and follow up of study participants.
doi:10.1371/journal.pone.0066627.g001
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sequence was generated by an independent researcher using
computer generated random number lists in blocks of 15, stratified
by 4 ethnic groups in a 1:1:1 ratio. The researcher gave
participants a study number on entry to the trial, and treatment
was allocated from the hospital pharmacy. Women were given
instructions to swallow the tablets whole and to avoid other
multivitamin supplements containing vitamin D. This trial was
conducted before national guidance on routinely providing advice
on vitamin D intake during pregnancy was introduced in March
2008 [14]. Investigators blind to original treatment allocation
assessed offspring at three years of age using a validated health
questionnaire and clinical assessment.
Outcome Assessments
The primary outcome was prevalence of ‘wheeze ever’ as
defined by the International Study of Asthma and Allergies in
Childhood (ISAAC) [20]. Secondary outcomes were recurrent
wheezing ($2 episodes of reported wheezing since birth), wheeze
in the year prior to assessment (ISAAC), wheeze with a positive
asthma predictive index (loose criteria) [21], reported history of
bronchodilator use, eczema ever (ISAAC), eczema in the year
prior to assessment (ISAAC), allergic rhinitis, history of doctor
diagnosed food allergy, history of lower respiratory tract infection
(LRTI) (any of bronchiolitis, bronchitis, croup, pneumonia or an
otherwise unspecified chest infection) and history of.4 episodes of
upper respiratory tract infections (URTI) per year (defined as a
positive answer to the question ‘how often does your child have an
upper respiratory tract infection, with at least two of the following
symptoms: cough, runny nose and fever?’).
Exhaled nitric oxide (eNO) was measured using an offline, tidal
breathing technique adherent to ATS/ERS guidelines [22].
Impulse oscillometry (IOS) was performed in accordance with
current international guidelines [23], before and 15 minutes after
inhalation of 400 mcg salbutamol sulphate via spacer (Volumatic,
Allen and Hanburys, Middlesex, UK). Resonant frequency, area
under the reactance curve, and resistance at 10 and 20 Hz were
chosen for data analysis. Bronchodilator responsiveness for each
parameter was measured as the percentage change seen post-
Table 1. Characteristics of study participants followed up at age three years.
Control Daily vitamin D Bolus vitamin D Combined vitamin D
(n=50) (n=56) (n=52) (n =108)
Baseline maternal 25(OH)D ,25 nmol/L, n/N (%) 24/50 (48) 25/56 (45) 22/52 (42) 47/108 (44)
Male sex, n/N (%) 27/50 (54) 32/56 (57) 26/52 (50) 58/108 (55)
Birth weight (g), mean (SD) 3268 (585) 3321 (525) 3290 (467) 3307 (497)
Ethnicity, n (%)
Asian 12 (24) 15 (27) 13 (25) 28 (26)
Middle Eastern 13 (26) 14 (25) 14 (26) 28 (26)
Black 12 (24) 14 (25) 13 (25) 27 (25)
White 13 (26) 13 (23) 12 (24) 25 (23)
GA at delivery (weeks), mean (SD) 40 (1) 39 (2) 40 (1) 39 (2)
Nulliparous mother, n/N (%) 23/50 (46) 20/56 (36) 21/52 (40) 41/108 (38)
Vaginal delivery, n/N (%) 29/50 (58) 35/56 (63) 28/52 (54) 63/108 (58)
Maternal smoking during pregnancy, n/N (%) 2/48 (4) 3/55 (5) 0/46 (0) 3/101 (3)
Presence of household smokers, n/N (%) 16/48 (33) 15/55 (27) 17/46 (37) 32/101 (32)
Number of children in household, mean (SD) 2 (1) 2 (1) 2 (1) 2 (1)
Age mother left full time education, mean (SD) 20 (3) 20 (4) 21 (4) 21 (4)
Child in nursery, n/N (%) 27/48 (56) 36/55 (65) 20/45 (44) 57/101 (56)
Cat or dog in household, n/N (%) 4/48 (8) 5/54 (9) 4/46 (9) 9/100 (9)
Maternal Fitzpatrick skin score grade 3–6, n/N (%) 28/44 (64) 33/49 (67) 28/43 (65) 61/92 (66)
Maternal regular vitamin intake at three years, n/N (%) 9/46 (20) 16/53 (30) 16/45 (36) 32/98 (33)
At least one parent with allergic disease, n/N (%) 23/45 (51) 35/53 (66) 21/45 (47) 56/98 (57)
Exclusively breast-fed for 4 months, n/N (%) 22/48 (46) 20/54 (37) 23/44 (52) 43/98 (44)
Any child vitamin supplementation, n/N (%) 30/48 (63) 34/55 (62) 30/46 (65) 64/101 (63)
Completed immunizations to date, n/N (%) 48/49 (98) 54/55 (98) 43/47 (91) 97/102 (95)
Age at time of assessment (months), median (IQR) 37.9 (36.9, 39.9) 37.1 (36.5, 38.8) 37.4 (36.5, 39.5) 37.3 (36.5, 39.0)
Child Fitzpatrick skin score grade 3–6, n (%) 29/42 (69) 34/48 (71) 29/43 (67) 63/91 (69)
Child BMI Z score age 3, mean (SD) 0.51 (1.48) 0.35 (1.15) 0.62 (1.15) 0.47 (1.15)
Child outdoors .1 hour/day, n/N (%) 32/48 (67) 34/53 (64) 33/45 (73) 67/98 (68)
Child TV/computer .2 hours/day, n/N (%) 24/48 (50) 18/53 (34) 17/45 (38) 35/98 (36)
Child 25(OH)D (nmol/L) age 3, median (IQR) 42 (27, 68) 35 (21, 66) 42 (30, 93) 41 (26, 72)
Data shown are for all participants analysed.
IQR = interquartile range, SD= standard deviation, GA= gestational age, SCBU= Special Care Baby Unit, BMI = Body mass index.
doi:10.1371/journal.pone.0066627.t001
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Table 2. Clinical outcomes at age three years. Combined vitamin D groups versus control.
Control Combined vitamin D RR OR P aOR
{
P
(%) (%) (95% CI) (95% CI) (95% CI)
Wheeze ever 14/50 (28) 26/108 (24) 0.86 (0.49, 1.50) 0.82 (0.38, 1.74) 0.60 0.73 (0.33, 1.65) 0.45
Recurrent wheezing 7/50 (14) 17/108 (16) 1.12 (0.50, 2.54) 1.15 (0.44, 2.97) 0.77 1.14 (0.42, 3.13) 0.80
Wheezing in the last year 8/50 (16) 17/108 (16) 0.98 (0.46, 2.13) 0.98 (0.39, 2.45) 0.97 0.95 (0.36, 2.51) 0.92
Wheeze with positive API 7/50 (15) 15/107 (14) 1.00 (0.44, 2.30) 1.00 (0.38, 2.64) 1.00 1.06 (0.37, 3.02) 0.91
Any bronchodilator use 4/49 (8) 24/104 (23) 2.83 (1.04, 7.71) 3.37 (1.10, 10.34) 0.03* 3.14 (0.96, 10.28) 0.06*
Eczema ever 15/49 (31) 30/102 (29) 0.96 (0.57, 1.61) 0.75 (0.35, 1.62) 0.47 0.72 (0.32, 1.61) 0.42
Eczema in the last year 7/49 (14) 20/103 (19) 1.36 (0.62, 3.00) 1.34 (0.52, 3.47) 0.55 1.52 (0.55, 4.21) 0.42
Atopy 7/27(26) 11/68 (16) 0.62 (0.27, 1.44) 0.56 (0.19, 1.66) 0.30 0.29 (0.07, 1.16) 0.08
Allergic rhinitis 7/49 (14) 11/101 (12) 0.76 (0.31, 1.85) 0.63 (0.22, 1.78) 0.38 0.69 (0.22, 2.13) 0.52
Food allergy diagnosis 3/49 (6) 12/102 (12) 1.92 (0.57, 6.50) 1.81 (0.48, 6.85) 0.38 1.93 (0.45, 8.29) 0.38
.4 URTI/year 7/50 (14) 20/103 (19) 1.39 (0.63, 3.06) 1.43 (0.55, 3.68) 0.46 1.34 (0.49, 3.68) 0.57
LRTI ever 11/50 (22) 31/101 (31) 1.40 (0.77, 2.54) 1.47 (0.64, 3.37) 0.37 1.60 (0.67, 3.85) 0.29
Primary health care records
Recurrent wheeze 3/31 (10) 10/70 (14) 1.48 (0.44, 5.00) 1.56 (0.40, 6.10) 0.52 1.47 (0.33, 6.55) 0.61
Eczema 6/31 (19) 10/70 (14) 0.74 (0.29, 1.85) 0.46 (0.23, 2.12) 0.52 0.63 (0.18, 2.16) 0.46
Food allergy 2/31 (6) 2/70 (3) 0.44 (0.07, 3.00) 0.43 (0.06, 3.18) 0.58 0.14 (0.00, 4.39) 0.26
RR = risk ratio, OR =unadjusted odds ratio, aOR = adjusted odds ratio, API = Asthma predictive index, URTI = upper respiratory tract infection, LRTI = lower respiratory
tract infection.
{Model adjusted for mother’s ethnic group, presence of household smokers, maternal smoking in pregnancy, exclusive breast-feeding to four months, any parental
allergic history, any child vitamin supplementation, number of children in the household, age mother left full-time education and baseline concentration of 25(OH)D in
maternal blood. n = 139 for primary outcome measure.
*Adjusted p-value for multiple testing non-significant at 20% level.
doi:10.1371/journal.pone.0066627.t002
Table 3. Clinical outcomes at age three years. Daily vitamin D versus control.
Control Daily Vitamin D RR OR P aOR
{
P
(%) (%) (95% CI) (95% CI) (95% CI)
Wheeze ever 14/50 (28) 11/56 (20) 0.70 (0.35, 1.40) 0.63 (0.26, 1.55) 0.31 0.56 (0.20, 1.57) 0.27
Recurrent wheezing 7/50 (14) 8/56 (14) 1.02 (0.40, 2.61) 1.02 (0.34, 3.06) 0.97 1.11 (0.32, 3.92) 0.87
Wheezing in the last year 8/50 (16) 8/56 (14) 0.89 (0.36, 2.20) 0.88 (0.30, 2.54) 0.81 0.88 (0.27, 2.90) 0.84
Wheeze with positive API 7/50 (14) 6/56 (11) 0.77 (0.28, 2.13) 0.74 (0.23, 2.36) 0.61 0.65 (0.15, 2.82) 0.57
Any bronchodilator use 4/49 (8) 10/56 (18) 2.23 (0.75, 6.67) 2.45 (0.72, 8.37) 0.15 2.24 (0.54, 9.33) 0.27
Eczema ever 15/49 (31) 15/54 (28) 0.91 (0.50, 1.66) 0.87 (0.37, 2.04) 0.75 0.61 (0.23, 1.67) 0.34
Eczema in the last year 7/49 (14) 11/55 (20) 1.40 (0.59, 3.33) 1.50 (0.53, 4.23) 0.44 1.31 (0.38, 4.54) 0.67
Atopy 7/27 (26) 4/36 (11) 0.41 (0.13, 1.27) 0.36 (0.09, 1.38) 0.13 0.36 (0.05, 2.94) 0.34
Allergic rhinitis 7/49 (14) 7/55 (13) 0.89 (0.34, 2.36) 0.88 (0.28, 2.70) 0.82 0.63 (0.17, 2.36) 0.49
Food allergy diagnosis 3/49 (6) 8/55 (15) 2.38 (0.67, 8.46) 2.61 (0.65, 10.45) 0.16 4.53 (0.52, 39.33) 0.17
.4 URTI/year 7/50 (14) 11/55 (20) 1.43 (0.60, 3.40) 1.54 (0.55, 4.33) 0.42 1.39 (0.41, 4.68) 0.60
LRTI ever 11/50 (22) 14/54 (26) 1.18 (0.59, 2.35) 1.24 (0.50, 3.07) 0.64 1.00 (0.35, 2.91) 1.00
Primary health care records
Recurrent wheeze 3/31 (10) 4/36 (11) 1.15 (0.28, 4.74) 1.17 (0.24, 5.67) 0.85 1.43 (0.21, 9.89) 0.71
Eczema 6/31 (19) 5/36 (14) 0.72 (0.24, 2.12) 0.67 (0.18, 2.46) 0.55 0.61 (0.13, 2.86) 0.53
Food allergy 2/31 (7) 2/36 (6) 0.86 (0.13, 5.76) 0.85 (0.11, 6.44) 0.88 - -
RR=Risk ratio, OR =unadjusted odds ratio, aOR = adjusted odds ratio, API = Asthma predictive index, URTI = upper respiratory tract infection, LRTI = lower respiratory
tract infection.
{Model adjusted for mother’s ethnic group, presence of household smokers, maternal smoking in pregnancy, exclusive breast-feeding to four months, any parental
allergic history, any child vitamin supplementation, number of children in the household, age mother left full-time education and baseline concentration of 25(OH)D in
maternal blood.
doi:10.1371/journal.pone.0066627.t003
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bronchodilator. See File S1 for description of IOS quality control
and exhaled nitric oxide assessment.
Allergic sensitisation was defined as a skin prick test wheal at
least 3 mm greater than the negative control (Glycerine) to one or
more of the aeroallergens tested at 15 minutes, in the context of an
appropriate response to the positive control (Histamine 10%).
House dust mite, alternaria, cladosporium, cat, dog, grass pollen,
silver birch pollen, peanut, milk and egg were tested (Stallergenes,
Antony, France).
Serum total IgE (ImmunoCAP, Phadia, Uppsala, Sweden),
25(OH)D and eosinophil count were determined on the day of the
child’s assessment. 25(OH)D was measured in mothers prior to
randomisation, and in offspring at birth (cord blood) using a radio-
immunoassay (DiaSorin, Stilwater, MN) in a clinical biochemistry
laboratory that participates in the international Vitamin D
external quality assessment program (DEQAS). Vitamin D
deficiency was defined as 25(OH)D ,25 nmol/L [24] and
sufficiency $ 50 nmol/L [24,25].
Primary health care records were obtained from participants’
general practitioners and reviewed by a single investigator (RJB),
blinded to treatment allocation. Children were categorised as
having ‘recurrent wheezing’ where $2 episodes of either
wheezing, or respiratory distress treated with bronchodilator were
recorded; ‘eczema’ if they had $2 attendances separated by $6
months where either topical corticosteroids were prescribed for
treatment of an itchy skin rash, or a doctor’s diagnosis of eczema
was made; and ‘food allergy’ if this diagnosis was recorded in any
part of the primary healthcare record.
Statistical Analysis
In the original study it was calculated that at least eight women
in each ethnic group for each arm of treatment would be needed
to demonstrate a significant difference in vitamin D levels at
delivery in the no treatment group vs. the supplemented groups
(power 90%, test of significance at 5% level). To account for drop-
outs, preterm delivery, and delivery at another hospital, 15 women
were allocated to each arm of treatment within each ethnic group
(n= 180).
With 180 participants and 80% successful follow up, this study
had 80% power with 2-sided alpha of 0.05 to detect a reduction in
wheeze from 34% in the children of non-supplemented mothers
[21] to 13% in the supplemented group. This level of risk
reduction would be consistent with some observational studies
[2,21]. For primary analyses, bolus and daily vitamin D
supplemented groups were analysed together and compared with
the control group. We also report separate analyses of bolus and
daily groups versus control, and of children born to mothers with
vitamin D deficiency at enrolment (defined as 25(OH)D
,25 nmol/L). Binary outcomes were analysed using risk ratios
and odds ratios for unadjusted analysis, and logistic regression for
adjusted analyses. Continuous outcomes were analysed using
linear regression. Potential confounding factors used in the
adjustment model were mother’s ethnic group, presence of
household smokers, maternal smoking in pregnancy, exclusive
breast-feeding to four months, any parental allergic history, any
child vitamin supplementation, number of children in the
household, age mother left full-time education and baseline
concentration of 25(OH)D in maternal blood. For all analyses,
Table 4. Clinical outcomes at age three years.
Control Bolus Vitamin D RR OR P aOR
{
P
(%) (%) (95% CI) (95% CI) (95% CI)
Wheeze ever 14/50 (28) 15/52 (29) 1.03 (0.56, 1.91) 1.04 (0.44, 2.47) 0.93 1.17 (0.44, 3.10) 0.75
Recurrent wheezing 7/50 (14) 9/52 (17) 1.24 (0.50 (3.07) 1.29 (0.44, 3.77) 0.65 1.91 (0.53, 6.75) 0.31
Wheezing in the last year 8/50 (16) 9/52 (17) 1.08 (0.45, 2.58) 1.10 (0.39, 3.12) 0.86 1.29 (0.40, 4.15) 0.66
Wheeze with positive API 7/50 (14) 9/51 (18) 1.26 (0.51, 3.12) 1.32 (0.45, 3.86) 0.62 2.01 (0.58, 6.99) 0.27
Any bronchodilator use 4/49 (8) 14/48 (29) 3.57 (1.27, 10.09) 4.63 (1.40, 15.34) 0.008* 5.43 (1.39, 21.20) 0.02*
Eczema ever 15/49 (31) 15/48 (31) 1.02 (0.56, 1.85) 1.03 (0.44, 2.44) 0.95 0.86 (0.32, 2.28) 0.76
Eczema in the last year 7/49 (14) 9/48 (19) 1.31 (0.53, 3.24) 1.39 (0.47, 4.08) 0.55 1.97 (0.47, 8.27) 0.36
Atopy 7/27 (26) 7/32 (22) 0.84 (0.34, 2.11) 0.80 (0.24, 2.66) 0.72 0.31 (0.05, 1.83) 0.20
Allergic rhinitis 7/49 (14) 4/46 (9) 0.61 (0.19, 1.94) 0.57 (0.16, 2.10) 0.40 0.91 (0.20, 4.11) 0.90
Food allergy diagnosed 3/49 (6) 4/47 (9) 1.36 (0.32, 5.78) 1.43 (0.30, 6.75) 0.65 1.31 (0.24, 7.18) 0.76
.4 URTI/year 7/50 (14) 9/48 (19) 1.34 (0.54, 3.31) 1.42 (0.48, 4.17) 0.53 1.72 (0.49, 6.04) 0.39
LRTI ever 11/50 (22) 17/47 (36) 1.64 (0.86, 3.14) 2.01 (0.82, 4.92) 0.12 2.87 (1.03, 8.03) 0.05*
Primary health care record
Recurrent wheeze 3/31 (10) 6/34 (18) 1.82 (0.50, 6.68) 2.00 (0.46, 8.80) 0.35 1.85 (0.36, 9.66) 0.47
Eczema 6/31 (19) 5/34 (15) 0.76 (0.26, 2.24) 0.72 (0.20, 2.64) 0.62 0.63 (0.11, 3.59) 0.60
Food allergy 2/31 (7) 0/34 (0) 0.0 (-, -) - - - -
Bolus vitamin D versus control.
RR = Risk Ratio, OR= unadjusted odds ratio, aOR = adjusted odds ratio, API = Asthma predictive index, URTI = upper respiratory tract infection, LRTI = lower respiratory
tract infection.
{Model adjusted for mother’s ethnic group, presence of household smokers, maternal smoking in pregnancy, exclusive breast-feeding to four months, any parental
allergic history, any child vitamin supplementation, number of children in the household, age mother left full-time education and baseline concentration of 25(OH)D in
maternal blood.
*Adjusted p-value for multiple testing non-significant at 20% level.
doi:10.1371/journal.pone.0066627.t004
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participants were analysed in the treatment groups to which they
were randomised.
Adjustment for multiple testing was performed using the
Benjamini and Hochberg method [26]. This works by evaluating
all the p-values from multiple analyses in order of significance, and
determining whether each one can truly be counted as significant
or not. For our analyses, there were 28 secondary clinical
outcomes (14 for the daily group, and 14 for the bolus group)
and the false discovery rate was controlled at 20%. All analyses
were performed using SPSS version 19.0 (IBM, Chicago USA).
Details of data handling and adjusted analysis are available in File
S1.
Results
Participant flow is shown in Figure 1. There was one twin
pregnancy of whom only the first born was included in analysis.
There were 4 deaths, all in the control group: one stillbirth at 41
weeks, one death aged two days (no further details available), one
death aged 16 hours from meconium aspiration and one child with
congenital abnormalities died post-operatively aged 17 months.
We successfully assessed the primary outcome measure in 158
(88%) of the cohort at age 3 years, between July 2010 and
February 2011. The follow up was stopped after all participants
had been successfully contacted or were considered lost to follow
up. 129 (72%) agreed to a review of their primary care record.
Atopy was assessed by skin test for 95 children (53%), acceptable
IOS data were available for 51 (28%), IgE level for 86 (48%), eNO
level for 62 (34%) and eosinophil count for 80 (44%). Character-
istics of the children and their mothers in each randomisation
group were similar at baseline, as shown in Table 1. As previously
reported [19], median cord 25(OH)D levels at delivery were
significantly higher in supplemented children compared to the
control group [control 17 nmol/l (interquartile range (IQR) 14–
22); daily dose 26 nmol/l (IQR 17–45); P,0.001; bolus dose
25 nmol/l (IQR 18–34); P,0.001)].
Effect of Prenatal Vitamin D Supplementation on Parent
Reported Wheezing, Allergic Disease and Respiratory
Infections
We found no significant difference in the primary outcome of
‘wheeze ever’ between treatment groups (any vitamin D vs. control
Table 2, daily vs. control Table 3, bolus vs. control Table 4).
There was also no difference between groups in prevalence of
eczema or atopy. We found significantly increased bronchodilator
use and higher prevalence of LRTI’s in the offspring of the bolus
group, but this did not remain significant after adjusting for
multiple testing at a 20% threshold. File S1 shows complete
analyses of these outcomes for the offspring of mothers with
Figure 2. Baseline respiratory resistance at 10 Hz (R10, A), 20 Hz (R20, B), resonant frequency (Fres, C) and area under the reactance
curve (AX, D) for control (n=13), daily (n=18), and bolus (n=20) vitamin D groups at age three years. Horizontal bars represent means.
No significant difference between groups.
doi:10.1371/journal.pone.0066627.g002
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vitamin D deficiency at baseline (any vitamin D vs. control, Table
S1 in File S1, daily vs. control, Table S2 in File S1, bolus vs.
control, Table S3 in File S1). We found no significant difference in
the primary outcome of ‘wheeze ever’, or for any secondary
outcomes between these groups.
Since 22 offspring were not followed up, sensitivity analyses
were performed to determine if this influenced the result for the
primary outcome. Two scenarios were considered – the first where
no drop-outs wheezed and the second where all drop-outs
wheezed (Table S4 in File S1). There was no significant difference
between groups in wheezing prevalence for either of these
scenarios.
For 122 children assessed at 3 years, cord blood 25(OH)D levels
were available. We found no difference between the natural
logarithm (Ln) of cord blood 25(OH)D levels in children with and
without a history of wheeze, atopy, eczema, any LRTI or .4
episodes of URTI per year (Table S5 in File S1). There was also
no correlation between Ln cord blood 25(OH)D level and Ln
Total IgE at age three years for 68 children (Beta coeffi-
cient =20.05, P= 0.72).
Effect of Prenatal Vitamin D Supplementation on Lung
Function and Bronchodilator Responsiveness
Fifty-one of 180 (28%) children provided acceptable IOS data
for analyses. We found no significant difference between groups in
baseline respiratory resistance at 10 or 20 Hz, resonant frequency,
area under the reactance curve or percentage response of these
parameters to bronchodilator, when data were analysed for the
two forms of prenatal vitamin D supplementation combined
(Table S6 in File S1), or separately (Figures 2 and 3).
Effect of Prenatal Vitamin D Supplementation on
Objective Measures of Allergic Inflammation
Total IgE levels, eNO and eosinophil counts were available for
106/180 (59%), 62/180 (34%) and 80/180 (44%) of offspring. We
found no significant difference between groups in these outcomes
assessed at age 3, when analysed for the two forms of prenatal
vitamin D supplementation combined (Table S7 in File S1) or
analysed separately (Figure 4).
Adverse Events
No adverse events related to treatment were reported in the
offspring.
Figure 3. Bronchodilator response for respiratory resistance at 10 Hz (R10, A), 20 Hz (R20, B), resonant frequency (Fres, C) and area
under the reactance curve (AX, D) for control (n =10), daily (n =15), and bolus (n=14) vitamin D groups at age three years. Horizontal
bars represent means. No significant difference between groups.
doi:10.1371/journal.pone.0066627.g003
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Discussion
In this randomised controlled trial of vitamin D supplementa-
tion in late pregnancy in a relatively deficient mixed race
population, daily supplementation with 800 IU ergocalciferol or
a single bolus dose of 200,000 IU cholecalciferol from 27 weeks
gestation did not prevent wheezing, allergic disease or influence
measures of lung function or allergic inflammation in offspring in
the first three years of life. We were unable to confidently exclude
an effect on some secondary outcome measures such as atopy at 3
years, where statistical power was limited. Our results suggest that
the most likely explanation for the finding of decreased wheezing
risk in offspring of mothers with a higher vitamin D intake during
pregnancy in observational studies [1–4], is confounding by other
dietary or lifestyle factors associated with vitamin D intake.
Our study has a number of limitations. First, we relied on a
subjective primary outcome measure and participants were not
blind to treatment allocation, which introduces a risk of reporter
bias. Investigators were, however, kept blind to treatment
allocation until database lock. Moreover the results of subjective
primary outcome measures were supported by the results of both
our secondary objective outcome assessments and a blinded
assessment of prospectively recorded healthcare records. Second,
this was a small study with limited statistical power, particularly for
detecting differences in objective outcomes. Our power calculation
was based on the study by Camargo et al [2], which estimated a
risk reduction for recurrent wheezing from 34% to 13%
comparing mothers with the highest quartile of daily vitamin D
intake (median 724 IU) to those in the lowest quartile of intake
(median 356 IU). However the prevalence of wheeze in our
control group was 28% thus reducing the power of the study. The
95% confidence interval for our primary outcome measure was
0.49 to 1.50, so we are unable to confidently exclude effects of
prenatal vitamin D supplementation on risk of wheezing, or on the
development of atopy especially in mothers treated with daily
vitamin D. Third, we did not assess vitamin D receptor
polymorphisms or other potentially important genotypic varia-
tions. It is possible that vitamin D supplementation is effective for
preventing wheezing or atopy in the presence of specific maternal
or infant genotypes, as suggested by others [27]. Fourth, women
from four ethnic groups were enrolled in this study, with
significant differences in baseline vitamin D levels between
Caucasian women and all other ethnic groups (data not shown).
Previous observational studies have predominantly studied Cau-
casians [2]. Although randomisation in this trial was stratified by
ethnicity, and we included baseline vitamin D in our adjusted
model, it is possible that this source of heterogeneity could have
masked positive findings. Fifth, supplementation with vitamin D
Figure 4. Measures of allergic inflammation at age three years. Ln IgE (A; n = 86), eNO (B; n = 62), and Ln eosinophil count (C; n = 90). Control
versus daily and bolus vitamin D. Horizontal bars represent means. No significant difference between groups.
doi:10.1371/journal.pone.0066627.g004
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only started at 27 weeks of gestation. It is known that immune cells
develop much earlier in fetal life [28], and that airway
development to the respiratory bronchioles is complete by 16
weeks gestation, [29]. It may be that supplementation earlier in
pregnancy, or indeed pre-conception, is necessary for protection
against childhood wheezing.
Finally, we are also unable to exclude the possibility that vitamin
D supplementation at a higher dose, might protect against early
childhood wheezing. Although the vitamin D doses used in this
trial were greater than the current recommended intake for
pregnant women of 400 IU/day during pregnancy in the United
Kingdom [14,17], and 600 IU in the United States [25], only a
small percentage of offspring had cord 25(OH)D levels in the
sufficient range (13% daily group, 3% bolus group). It has recently
been shown that doses of 4000 IU of vitamin D daily are safe and
effective for short term treatment of vitamin D deficiency during
pregnancy [30], although the long term effects on child health
have not been studied. Two on-going trials, the Vitamin D
Prenatal Asthma Reduction Trial (NCT00920621), and ABCvi-
taminD (NCT00856947) are specifically exploring the effects of
earlier and higher dose prenatal vitamin D supplementation on
child health.
Two recent observational studies that documented prenatal
vitamin D status by measuring cord blood 25(OH)D concentra-
tion, found relationships with allergic sensitisation and/or
wheezing in early childhood [8,31]. When we analysed our own
data on cord blood 25(OH)D concentration and wheezing, atopy,
total IgE level and frequency of respiratory infection in the first
three years, no significant relationship was found. While our
interventions did result in at least 50% higher cord blood
25(OH)D concentrations compared with no treatment, cord blood
levels were still significantly lower in the intervention groups than
in these studies. The results of our randomised controlled trial do
not support a strong causal relationship between low prenatal
vitamin D status within the deficient/insufficient range and
increased risk of allergic sensitization or wheezing in early
childhood. We are unable to confidently exclude a similar
relationship in more vitamin D sufficient populations [8].
The findings of our study are specific to a population of vitamin
D deficient women (half had baseline 25(OH)D levels below
25 nmol/L) and two specific forms of prenatal vitamin D
supplementation. The doses of supplementation were chosen
pragmatically, were not stratified based on individual vitamin D
status or genotype, and response to treatment was not monitored
before delivery. The study population was not selected for allergy
or asthma risk and, as a mixed race urban population, is
representative of many populations of pregnant women worldwide
[32]. Although these findings cannot automatically be generalised
to other populations of pregnant women, one might expect
prenatal vitamin D supplementation to show its clearest clinical
effects in a deficient population such as this.
In summary we found no evidence for a protective effect of
prenatal vitamin D supplementation from 27 weeks gestation on
childhood wheezing, allergic disease, lung function or markers of
airway inflammation in the first 3 years of life. Given the modest
effects on cord blood vitamin D achieved by these interventions,
the safety and efficacy of higher dose prenatal vitamin D
supplementation strategies need to be explored.
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